Ryosuke Shirasaki

Dr. Ryosuke Shirasaki

Department of Hematology&Oncology, Teikyo University School of Medicine, Tokyo 173-0003, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Medicine
Verified
Journal Article
Open access
TMTakuji Matsuo
Takuji Matsuo
HTHaruko Tashiro
Haruko Tashiro
Ryosuke ShirasakiRyosuke Shirasaki
Ryosuke Shirasaki
RSRitsu Sumiyoshi
Ritsu Sumiyoshi
TYTadashi Yamamoto
Tadashi Yamamoto
NSNaoki Shirafuji
Naoki Shirafuji
We investigated the potential of nutritional and inflammatory parameters as prognostic factors for follicular lymphoma (FL), and also examined the predictive value of the early progression of disease within 24 months of first-line chemo-immunotherapy (POD24). We retrospectively analyzed 46 patients with FL admitted to Teikyo University Hospital and treated with chemo-immunotherapy between May 2009 and July 2019. Physical characteristics, blood parameters, and markers or scores for consumptive/inflammatory and nutritional conditions were used as variables. Nine parameters correlated with poor overall survival (OS) in univariate analysis: An Eastern Cooperative Oncology Group (ECOG) scale performance status (PS) ≥2, five or more involved nodal sites, positive bone marrow (BM) involvement, a serum albumin level 0.5 mg/dL, lactate dehydrogenase (LD) higher than the upper normal limit (UNL), high-density lipoprotein cholesterol (HDL-C) <40 mg/dL, modified Glasgow prognostic score of 1–2, and the geriatric nutritional risk index <82. In multivariate analysis, ECOG PS ≥2, positive BM involvement, and a serum HDL-C level UNL, and HDL-C <40 mg/dL by Fisher’s exact test. These results indicate that low serum HDL-C levels appear to be important for predicting the risk of POD24 and the worse prognosis of FL.